6
KLBF0209.TXT

KLBF
Kalbe Farma
Af          :
Sector Code : 53
Sector Name : PHARMACEUTICALS

(In thousand rupiah except Par Value, Closing Price and Ratios)

Financial Statement Date    : 30-Sep-2002
Fiscal Year Ends            : Dec
Months Covered in Income St : 9

Summary of Balance Sheet
  Receivables               :     531,385,623.31
  Inventories               :     348,145,696.07
  Current Assets            :   1,329,355,288.59
  Fixed Assets              :     453,339,190.64
  Other Asstes              :      16,864,993.69
  Total Assets              :   2,155,876,330.54
  Current Liabilities       :     535,467,909.17
  Longterm Liabiities       :   1,005,739,926.25
  Total Liabilities         :   1,541,207,835.43
  Authorized                :       8,500,000.00
  Paid-up Capital           :     406,080,000.00
  Par Value                 :                100
  Paid-up Capital Shares    :       4,060,800.00
  Retained Earnings         :      29,626,189.99
  Total Equity              :     452,375,549.24
  Minority Interest         :     162,292,945.88

Summary of Income Statement
  Total Sales               :   1,868,795,285.18
  Cost of Good Sold         :     939,199,582.94
  Gross Profit              :     929,595,702.24
  Operating Profit          :     375,659,750.09
  Other Income              :      40,787,206.56
  Eearning Before Tax       :     416,446,956.65
  Tax                       :     142,840,076.83
  Net Income                :     230,939,105.31
  Closing Price             :             240.00

Per Share Data (Rp)
  Eps                       :              75.83
  Book Value                :             111.40

Financial Ratios
  Debt Equity Ratio (X)     :               3.41
  Roa (%)                   :              14.28
  Roe (%)                   :              68.07
  Npm (%)                   :              16.48
  Opm (%)                   :              26.80

Cash Flow
  CF from Operating Activities                        :     205,839,843.58
  CF from Investing Activities                        :     -52,266,857.13
  CF from Financing Activities                        :     -43,622,169.70
  Net Increase in Cash & Cash Equivalent              :      97,772,503.95
  Cash & Cash Equivalent at The Beginning of The Year :     247,166,074.65
  Cash & Cash Equivalent at The End of The Year       :     344,938,578.61

 
 
 
